Drug General Information |
Drug ID |
D09ETH
|
Former ID |
DIB016237
|
Drug Name |
E-7050
|
Synonyms |
C-Met and VEGF-2 tyrosine kinase inhibitor (oral, cancer), Eisai
|
Drug Type |
Small molecular drug
|
Indication |
Head and neck cancer [ICD9: 140-149, 140-229; ICD10:C07-C14, C32-C33]
|
Phase 1 |
[1],
[2]
|
Company |
Eisai Co Ltd
|
Structure |
|
Download
2D MOL
3D MOL
|
Formula |
C33H37F2N7O4
|
InChI |
InChI=1S/C33H37F2N7O4/c1-40-16-18-41(19-17-40)24-9-14-42(15-10-24)32(45)39-29-21-26(8-13-36-29)46-25-6-7-28(27(35)20-25)38-31(44)33(11-12-33)30(43)37-23-4-2-22(34)3-5-23/h2-8,13,20-21,24H,9-12,14-19H2,1H3,(H,37,43)(H,38,44)(H,36,39,45)
|
InChIKey |
UQRCJCNVNUFYDX-UHFFFAOYSA-N
|
PubChem Compound ID |
|
PubChem Substance ID |
24765550, 28721555, 40652761, 141053681, 152258444, 160644595, 160647280, 162009761, 162011993, 162108794, 163312255, 164045124, 172918939, 174525694, 174531528, 185990484, 198990522, 223388544, 224233676, 225848215, 227908873, 247721050, 249565639, 249814484, 252160604, 252441725, 252451558, 252553660
|
Target and Pathway |
Target(s) |
Vascular endothelial growth factor receptor 2 |
Target Info |
Modulator |
[3]
|
Hepatocyte growth factor receptor |
Target Info |
Modulator |
[3]
|
KEGG Pathway
|
Ras signaling pathway
|
Rap1 signaling pathway
|
Cytokine-cytokine receptor interaction
|
Endocytosis
|
PI3K-Akt signaling pathway
|
VEGF signaling pathway
|
Focal adhesion
|
Proteoglycans in cancerhsa04014:Ras signaling pathway
|
Axon guidance
|
Adherens junction
|
Bacterial invasion of epithelial cells
|
Epithelial cell signaling in Helicobacter pylori infection
|
Malaria
|
Pathways in cancer
|
Transcriptional misregulation in cancer
|
Proteoglycans in cancer
|
MicroRNAs in cancer
|
Renal cell carcinoma
|
Melanoma
|
Central carbon metabolism in cancer
|
NetPath Pathway
|
IL2 Signaling Pathway
|
PANTHER Pathway
|
Angiogenesis
|
VEGF signaling pathway
|
Pathway Interaction Database
|
HIF-2-alpha transcription factor network
|
Beta3 integrin cell surface interactions
|
Signaling events mediated by TCPTP
|
SHP2 signaling
|
S1P1 pathway
|
VEGF and VEGFR signaling network
|
Integrins in angiogenesis
|
Signaling events mediated by VEGFR1 and VEGFR2
|
Notch-mediated HES/HEY networkmet_pathway:Signaling events mediated by Hepatocyte Growth Factor Receptor (c-Met)
|
Arf6 signaling events
|
Posttranslational regulation of adherens junction stability and dissassembly
|
Direct p53 effectors
|
Syndecan-1-mediated signaling events
|
Stabilization and expansion of the E-cadherin adherens junction
|
a6b1 and a6b4 Integrin signaling
|
FGF signaling pathway
|
Regulation of retinoblastoma protein
|
Reactome
|
Neurophilin interactions with VEGF and VEGFR
|
VEGF binds to VEGFR leading to receptor dimerization
|
Integrin cell surface interactions
|
EPHA-mediated growth cone collapse
|
VEGFA-VEGFR2 Pathway
|
VEGFR2 mediated cell proliferationR-HSA-416550:Sema4D mediated inhibition of cell attachment and migration
|
WikiPathways
|
Focal Adhesion
|
Nifedipine Activity
|
Cardiac Progenitor Differentiation
|
Signaling by VEGF
|
AngiogenesisWP366:TGF beta Signaling Pathway
|
Signaling of Hepatocyte Growth Factor Receptor
|
Extracellular vesicle-mediated signaling in recipient cells
|
Signaling Pathways in Glioblastoma
|
miR-targeted genes in squamous cell - TarBase
|
miR-targeted genes in muscle cell - TarBase
|
miR-targeted genes in lymphocytes - TarBase
|
miR-targeted genes in epithelium - TarBase
|
Semaphorin interactions
|
References |
REF 1 | ClinicalTrials.gov (NCT02533102) Pharmacokinetics and Food Effect of Single Oral Dose of E7050 in Healthy Volunteers. |
---|
REF 2 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7956). |
---|
REF 3 | E7050: a dual c-Met and VEGFR-2 tyrosine kinase inhibitor promotes tumor regression and prolongs survival in mouse xenograft models. Cancer Sci. 2010 Jan;101(1):210-5. |